Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response.
The highly anticipated Lipid Nanoparticle Immunogenicity & Toxicity Summit takes place this December to unite 80+ senior leaders as the definitive meeting for clinical pharmacology, immunogenicity, bioanalytical development leaders to stay at the forefront, arming you with practical takeaways and lessons learned.
Across 3 days, we will delve into:
- Immunomodulation strategies to increase the therapeutic window
- Translatable preclinical models to revolutionize clinical relevancy
- Dosing considerations dependent on your disease indication, route of administration and patient group for improved safety
And much more!
Hear the latest insights and case studies to optimize your prediction of PKPD, accurate dosing regime and immuno-modulation of LNP for long-term patient safety and potency.
Across 3 days, with over 6 hours of networking, this is your must-attend summit in 2022, to join the likes of AstraZeneca, Bristol Myers Squibb, NanoVation Therapeutics, Vertex Pharmaceuticals to lay the foundation for robust immunotoxicity protocols, propelling your novel pipeline growth.
Download the full event guide to find out more.
This post was originally published on Source Link